Hong Kong Pharmaceuticals Stock News

As geopolitical tensions in the Middle East and volatile energy prices continue to influence global markets, Asian equities have been impacted by these developments, with investors closely watching how economies in the region navigate rising inflationary pressures. In this context, dividend stocks can offer a measure of stability and income potential, making them an attractive option for those looking to weather uncertain times while benefiting from consistent payouts.

Debt repurchase prompts fresh look at China Water Affairs Group China Water Affairs Group (SEHK:855) has repurchased and cancelled US$25,000,000 of its outstanding notes, about 7.1% of the original issue. This trims the remaining balance to US$325,000,000. See our latest analysis for China Water Affairs Group. The HK$4.94 share price has recently seen a 1.65% 1 day gain, but this follows a 6.44% year to date share price decline and a 22.04% 1 year total shareholder return decline, suggesting...

Why SY Holdings Group (SEHK:6069) is Back on Investors’ Radar SY Holdings Group (SEHK:6069) has drawn fresh attention after its 2025 earnings showed higher net income alongside slightly lower revenue, paired with a special dividend and a recommended increase in the final cash dividend. See our latest analysis for SY Holdings Group. Despite the latest earnings and dividend announcements, the 7 day share price return of a 10.0% decline and the 30 day share price return of a 13.48% decline at...

Why Country Garden Services Holdings is back in focus Country Garden Services Holdings (SEHK:6098) has drawn fresh attention after reporting full year 2025 results, which showed higher sales but a sharp drop in net income, alongside the completion of a sizeable share buyback program. See our latest analysis for Country Garden Services Holdings. The share price reaction has been mixed, with a 3.32% 1 day share price return and a 1.54% 7 day share price return, set against a 6.33% 30 day share...

United Company RUSAL International (SEHK:486) has released its full year 2025 results, reporting sales of US$14.8b and a net loss of US$455 million, a clear change from the prior year’s profit. See our latest analysis for United Company RUSAL International. The earnings release and upcoming board meeting on March 20 come against a weak backdrop, with a 30 day share price return of a 23.08% decline and a year to date share price return of a 15.11% decline, while the 3 year total shareholder...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Everest Medicines Limited recently reported full-year 2025 results, with sales of CNY 1,706.68 million versus CNY 706.68 million a year earlier and a net loss of CNY 297.77 million compared with CNY 1,041.38 million, alongside presentations at the American College of Cardiology 75th Annual Scientific Session in New Orleans in March 2026. The sharp increase in revenue and much smaller loss per share point to materially improved operating efficiency that could reshape how investors view the...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just received Chinese regulator approval for its SKB103 IND in advanced solid tumors, marking a new clinical milestone that comes alongside recent earnings and oncology trial updates. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The regulatory green light for SKB103 comes after a series of oncology updates and full-year 2025 results. The share price has reacted, with a 7.07% 1-day share price return and 18.12% 30-day...

Wynn Macau (SEHK:1128) has drawn fresh attention after releasing full year 2025 results that show revenue broadly steady while net income declined, alongside a higher recommended final ordinary dividend. See our latest analysis for Wynn Macau. The full year results and higher proposed dividend come after a mixed share price run, with a 7 day share price return of 4.50%, a 90 day share price return of 6.86% and a year to date share price return of 7.17%, while the 1 year total shareholder...

Looking at MicroPort Scientific Corporation's ( HKG:853 ) insider transactions over the last year, we can see that...

Shareholders appeared unconcerned with China Petroleum & Chemical Corporation's ( HKG:386 ) lackluster earnings report...

The subdued stock price reaction suggests that Besunyen Holdings Company Limited's ( HKG:926 ) strong earnings didn't...

Cryofocus Medtech (Shanghai) (SEHK:6922) has just posted its FY 2025 first half results, with revenue of ¥51.1 million and a basic EPS loss of ¥0.10, while trailing 12 month figures show revenue of ¥95.3 million and a basic EPS loss of ¥0.16. The company has seen revenue move from ¥19.5 million in the first half of FY 2024 to ¥34.1 million in the second half and then to ¥51.1 million in the first half of FY 2025, alongside net income losses of ¥52.2 million, ¥52.2 million and ¥23.8 million...

Changjiu Holdings (SEHK:6959) has just released its FY 2025 numbers, with first half revenue of C¥696.7 million and basic EPS of C¥0.33. This sets the stage against a trailing 12 month line that shows C¥1.62 billion in revenue and EPS of C¥0.70. Over recent reporting periods, revenue has moved from C¥337.2 million and EPS of C¥0.29 in 1H FY 2024, to C¥340.4 million and EPS of C¥0.51 in 2H FY 2024, before reaching the latest 1H FY 2025 levels. This leaves investors to weigh this earnings...

Dongguan Rural Commercial Bank (SEHK:9889) has wrapped up FY 2025 with fourth quarter revenue of C¥1.4b and net income of C¥209.3m, alongside trailing twelve month EPS of C¥0.56 on revenue of C¥8.3b. Over recent periods, revenue has ranged from C¥2.5b in the first quarter of 2025 to C¥1.4b in the fourth quarter, with quarterly net income moving between C¥1.6b and C¥209.3m, and trailing net profit margin easing from 52.4% to 46.4% over the last year. This puts the focus squarely on how...

Deewin Tianxia (SEHK:2418) has released its FY 2025 figures, reporting first half revenue of about CN¥1.1b and basic EPS of CN¥0.04. This is set against a trailing 12‑month picture where EPS is CN¥0.03 on revenue of roughly CN¥2.8b and net income of CN¥68.3m. Over recent periods the company’s revenue has moved from about CN¥1.3b in 1H 2024 to CN¥1.3b in 2H 2024, and then to roughly CN¥1.1b in 1H 2025. Basic EPS shifted from CN¥0.05 in 1H 2024 to CN¥0.02 in 2H 2024, and then to CN¥0.04 in 1H...

CSSC Offshore & Marine Engineering (Group) (SEHK:317) just closed FY 2025 with fourth quarter revenue of C¥6.2b and basic EPS of C¥0.25, alongside trailing twelve month EPS of C¥0.71 on revenue of C¥20.5b. This was capped by earnings growth of 167.3% over the last year. Over recent periods the company has seen quarterly revenue range from C¥3.6b to C¥6.7b with EPS moving between C¥0.03 and C¥0.25, while trailing twelve month net income reached C¥1.0b as margins improved from 1.9% to 4.9%...

Great Wall Motor (SEHK:2333) has wrapped up FY 2025 with fourth quarter revenue of CN¥69.2b and basic EPS of CN¥0.15, while trailing twelve month figures show revenue of CN¥222.8b and EPS of CN¥1.16. Over recent quarters the company has seen revenue move from CN¥59.9b in Q4 2024 to CN¥69.2b in Q4 2025, with quarterly EPS shifting from CN¥0.27 to CN¥0.15. This sets up an earnings picture where a 4.4% trailing net margin and a CN¥4.1b one off gain leave investors weighing how durable the...

China Isotope & Radiation (SEHK:1763) has opened FY 2025 with first half revenue of C¥2,857.8 million and basic EPS of C¥0.54, setting the tone for how the year is shaping up after a strong back half of FY 2024. The company has seen revenue move from C¥2,810.3 million in 1H 2024 to C¥4,764.5 million in 2H 2024, with basic EPS rising from C¥0.48 to C¥0.79 over the same periods, and trailing twelve month EPS most recently coming in at C¥1.02. For investors, the key question now is how these...

Weiye Holdings (SEHK:1570) has released its FY 2025 figures with first half revenue of C¥11.4 million and a basic EPS loss of C¥0.11, while trailing twelve month revenue came in at C¥59.1 million with a basic EPS loss of C¥2.31. Over recent periods the company has seen first half revenue move from C¥1,352.0 million in 2023 to C¥32.0 million in 2024 and C¥11.4 million in 2025, alongside first half basic EPS losses of C¥0.21, C¥0.35 and C¥0.11 respectively. With the share price at C¥7.20, this...

Datang International Power Generation (SEHK:991) has reported its FY 2025 results with fourth quarter revenue of C¥31.9b and basic EPS of C¥0.0256, while trailing twelve month EPS stands at C¥0.3155 on revenue of C¥121.3b. Over the past year, trailing net income excluding extra items increased from C¥4,506.2m to C¥7,386.3m, and trailing net profit margin moved from 3.6% to 6.1%, pointing to more earnings being retained from each unit of sales. For investors, that shift in profitability is a...

Future Machine (SEHK:1401) has just posted its FY 2025 first half results, with revenue of C¥1.6b and net income of C¥11.2m translating to basic EPS of C¥0.011. This is set against a trailing twelve month picture of C¥4.35b in revenue, C¥41.4m in net income and C¥0.0318 in EPS. Over recent periods the company has reported revenue of C¥1.26b in 1H 2024, C¥1.66b in 2H 2024, and then C¥1.6b in 1H 2025, while basic EPS has ranged from C¥0.0099 to C¥0.0065 to C¥0.011. These headline shifts sit...

WellCell Holdings (SEHK:2477) opened FY 2025 with first half revenue of CN¥90.1 million and net income of CN¥7.7 million, translating to basic EPS of CN¥0.007717 as investors weigh these figures against a current share price of HK$19.60. Over recent periods the company has seen revenue move from CN¥106.1 million in 1H 2024 to CN¥172.1 million in 2H 2024 before landing at CN¥90.1 million in 1H 2025, while basic EPS shifted from CN¥0.010885 to CN¥0.009418 and then to CN¥0.007717. These trends...

China Sunshine Paper Holdings (SEHK:2002) has reported its FY 2025 first half results with revenue of C¥3.6b and basic EPS of C¥0.08, setting a cautious tone after a period where margins have come under pressure. Over the past three reported halves, revenue has moved from C¥4.0b in 1H 2024 to C¥4.1b in 2H 2024 and then to C¥3.6b in 1H 2025. Over the same timeframe, basic EPS shifted from C¥0.18 to C¥0.08, alongside a trailing 12 month net profit margin of 2.1% versus 3.5% the prior year. For...